Drug firm Novartis India has completed the transaction to sell its animal health business to Elanco India, an affiliate of Eli Lilly.
“Following the approval from the Foreign Investment Promotion Board (FIPB), the Centre and the Competition Commission of India, we wish to inform you that the transaction for the transfer of the company’s animal health division to Elanco India has been completed,” Novartis India said in a BSE filing today.
Swiss drug major Novartis had closed the transfer of the animal health business to US-based Eli Lilly globally in January last year.
In April 2014 Novartis had agreed to sell its global animal health business to Eli Lilly and Co for about $5.4 billion in an all-cash transaction.
Shares of Novartis India were trading at Rs 808 per scrip on the BSE, down 0.12 per cent from the previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.